🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Aaron S. Rosenberg

Johns Hopkins University

ORCID: 0000-0003-0714-734X

Also affiliated with Johns Hopkins Medicine, Epworth Hospital, Comprehensive Blood & Cancer Center, UC Davis Comprehensive Cancer Center, University of California, Davis

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 9 papers. Top paper: “Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis”.

Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis

Blood(2024)10.1182/blood.2024025939

N/A

0.621DataRank · unranked

10 citations

Rachael Sexton, Andrew J. Cowan, Aaron S. Rosenberg, Sikander Ailawadhi, S. Vincent Rajkumar +9 more

Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center

Frontiers in Oncology(2021)10.3389/fonc.2021.649209

N/A

0.606DataRank · unranked

56 citations

Benjamin N. Moskoff, David J. Benjamin, Rasmus T. Hoeg, Aaron S. Rosenberg, Mehrdad Abedi +3 more

Utilization of Autologous Hematopoietic Cell Transplantation Over Time in Multiple Myeloma: A Population-Based Study

Clinical Lymphoma Myeloma & Leukemia(2023)10.1016/j.clml.2023.12.009

N/A

0.330DataRank · unranked

8 citations

Ann Brunson, Aaron S. Rosenberg, Sara J. Schonfeld, Bryan Valcárcel, Renata Abrahão +8 more

Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients

Blood Cancer Journal(2021)10.1038/s41408-020-00400-4

N/A

0DataRank · unranked

23 citations

Ann Brunson, Joseph M. Tuscano, Brian A. Jonas, Rasmus T. Hoeg, Ted Wun +2 more

Association of Morbid Progression With Overall Survival Among Patients With Multiple Myeloma: Validation of the Progression-free Survival Endpoint

Clinical Lymphoma Myeloma & Leukemia(2020)10.1016/j.clml.2020.12.021

N/A

0DataRank · unranked

7 citations

Thierry Façon, Kejal Parikh, Weiyuan Chung, Shankar Srinivasan, Stanley Kotey +2 more

A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysis

Blood Advances(2025)10.1182/bloodadvances.2025016845

N/A

0DataRank · unranked

2 citations

Tamer Othman, Paul Frankel, Christopher Ruel, Christina Poh, Samantha Herbert +20 more

Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center

Leukemia Research(2022)10.1016/j.leukres.2022.106885

N/A

0DataRank · unranked

8 citations

Benjamin Moskoff, Gwendolyn Ho, Matthew E. Tenold, Tali Azenkot, Margaret L. Krackeler +12 more

A Phase I Study of Everolimus and Bendamustine in Patients With Relapsed/Refractory Lymphoid Hematologic Malignancies

Clinical Lymphoma Myeloma & Leukemia(2020)10.1016/j.clml.2020.02.006

N/A

0DataRank · unranked

3 citations

JULIAN R. DAVIS, Brian A. Jonas, Joseph M. Tuscano, Aaron S. Rosenberg, Mehrdad Abedi +1 more

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.18_suppl.lba3

N/A

0DataRank · unranked

31 citations

Susanna Jacobus, Adam D. Cohen, Matthias Weiss, Natalie S. Callander, Avina A. Singh +15 more